Parent-of-origin Effect in Schizophrenia and Non-affective Psychoses: Evidence from Dermatoglyphics.

Objective: This study aims at examining "parent-of-origin effect" (POE) in dermatoglyphic patterns among patients with schizophrenia and non-affective psychoses.

Materials And Methods: Dermatoglyphic comparison was carried out for schizophrenia patients (n=200) and healthy controls (HC) (n=100). In addition, the effect of family history and POE was examined in the dermatoglyphic pattern.

Family history correlates of digit ratio abnormalities in schizophrenia.

Background: The differences in digit ratio are proposed to arise due to differential effects of sex steroids on the growth of finger bones. In this study, we sought to examine the sex differences and the influence of family history of psychosis on digit ratio in patients with schizophrenia compared to matched healthy controls (HCs).

Materials And Methods: Digit ratio (2D: 4D) was examined for a large sample of schizophrenia patients (n=200) and HC (n=177) to evaluate the potential effects of family history.

Chlorpromazine induced cataract in a young patient with schizophrenia.

There is resurgence of first generation antipsychotics use due to the metabolic side effects associated with the use of second generation antipsychotics. Lenticular and corneal abnormalities were reported earlier with Chlorpromazine. However, there has not been much interest in the recent past.

Rimonabant-induced catatonia in schizophrenia: A case report.

Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported.

Olanzapine-induced clinical seizure: a case report.

Atypical antipsychotics are known to be associated with electroencephalogram abnormalities. Olanzapine can lower seizure threshold and induce epileptiform discharges. However in patients on olanzapine for the treatment of a primary psychiatric disorder, clinical seizure is a rare occurrence.